相似文献
1
A user's guide to the NINDS rt-PA stroke trial database.
PLoS Med. 2008 May 20;5(5):e113. doi: 10.1371/journal.pmed.0050113.
2
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
Stroke. 2008 Mar;39(3):924-8. doi: 10.1161/STROKEAHA.107.490375. Epub 2008 Jan 31.
3
Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
Stroke. 2004 Jan;35(1):147-50. doi: 10.1161/01.STR.0000105396.93273.72. Epub 2003 Dec 4.
4
[Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France].
Rev Neurol (Paris). 2006 Nov;162(11):1109-17. doi: 10.1016/s0035-3787(06)75123-2.
5
NINDS Stroke Trial data reanalysis leaves issues unresolved.
Stroke. 2005 Mar;36(3):529-30; author reply 529-30. doi: 10.1161/01.str.0000154861.96280.29.
6
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
Stroke. 2004 Apr;35(4):904-11. doi: 10.1161/01.STR.0000121641.77121.98. Epub 2004 Mar 11.
7
Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
Stroke. 2000 Dec;31(12):2912-9. doi: 10.1161/01.str.31.12.2912.
8
Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.
Stroke. 2005 Jan;36(1):62-5. doi: 10.1161/01.STR.0000150515.15576.29. Epub 2004 Nov 29.
9
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
Lancet. 2004 Mar 6;363(9411):768-74. doi: 10.1016/S0140-6736(04)15692-4.
10
The Interventional Management of Stroke (IMS) II Study.
Stroke. 2007 Jul;38(7):2127-35. doi: 10.1161/STROKEAHA.107.483131. Epub 2007 May 24.
引用本文的文献
1
Risk of selection bias assessment in the NINDS rt-PA stroke study.
BMC Med Res Methodol. 2022 Jun 15;22(1):172. doi: 10.1186/s12874-022-01651-4.
2
Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome.
Stroke. 2021 Jan;52(1):132-141. doi: 10.1161/STROKEAHA.119.028687. Epub 2020 Dec 15.
3
Data sharing: experience of accessing individual patient data from completed randomised controlled trials in vascular and cognitive medicine.
BMJ Open. 2020 Sep 9;10(9):e038765. doi: 10.1136/bmjopen-2020-038765.
4
Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation.
J Gen Intern Med. 2019 Apr;34(4):583-590. doi: 10.1007/s11606-018-4796-9. Epub 2019 Jan 8.
5
Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation - A microsimulation study.
PLoS One. 2018 Jul 11;13(7):e0199593. doi: 10.1371/journal.pone.0199593. eCollection 2018.
6
Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis.
J Neurol. 2017 Jun;264(6):1227-1235. doi: 10.1007/s00415-017-8520-1. Epub 2017 May 26.
7
TURN Score Predicts 24-Hour Cerebral Edema After IV Thrombolysis.
Neurocrit Care. 2016 Jun;24(3):381-8. doi: 10.1007/s12028-015-0198-6.
8
TURN Score Predicts 90-day Outcome in Acute Ischemic Stroke Patients After IV Thrombolysis.
Neurocrit Care. 2015 Oct;23(2):172-8. doi: 10.1007/s12028-015-0154-5.
9
TURN: A Simple Predictor of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.
Neurocrit Care. 2015 Oct;23(2):166-71. doi: 10.1007/s12028-015-0131-z.
10
Thrombolysis for acute ischaemic stroke.
Cochrane Database Syst Rev. 2014 Jul 29;2014(7):CD000213. doi: 10.1002/14651858.CD000213.pub3.
本文引用的文献
1
Thrombolytic therapy for acute ischemic stroke - Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?
CJEM. 2001 Jul;3(3):183-5. doi: 10.1017/s1481803500005510.
2
Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.
Stroke. 2007 Feb;38(2):414-6. doi: 10.1161/01.STR.0000254580.39297.3c. Epub 2007 Jan 18.
3
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Ann Emerg Med. 2005 Sep;46(3):243-52. doi: 10.1016/j.annemergmed.2005.02.013.
4
Contradicted and initially stronger effects in highly cited clinical research.
JAMA. 2005 Jul 13;294(2):218-28. doi: 10.1001/jama.294.2.218.
5
Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research.
J Neurosci Methods. 2005 Apr 30;143(2):209-16. doi: 10.1016/j.jneumeth.2004.10.002. Epub 2004 Dec 8.
6
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
Ann Emerg Med. 2005 Apr;45(4):377-84. doi: 10.1016/j.annemergmed.2004.06.021.
7
Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Stroke. 2004 Oct;35(10):2418-24. doi: 10.1161/01.STR.0000140891.70547.56. Epub 2004 Sep 2.
8
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
Lancet. 2004 Mar 6;363(9411):768-74. doi: 10.1016/S0140-6736(04)15692-4.
9
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial.
Neurology. 2003 Oct 28;61(8):1158-9. doi: 10.1212/01.wnl.0000086809.46485.a1.
10
Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little.
Med J Aust. 2003 Oct 6;179(7):333-4. doi: 10.5694/j.1326-5377.2003.tb05584.x.
Zotero 插件